Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)

Key Inclusion Criteria:

- Males and females between 18-75 years of age (Cohorts 1-9: 18-75 years and Cohorts
10-11: ≥ 18 years); inclusive based on the date of the screening visit

- Willing and able to provide informed consent prior to any study specific procedures
being performed

- Meets the following conditions (Cohorts 1-6 and 9):

- Clinical diagnosis of non-alcoholic fatty liver disease and evidence of F2-3
fibrosis

- For Cohorts 7 and 8, participants must have a clinical diagnosis of NAFLD and
cirrhosis

- For Cohorts 10 and 11, individuals must have a clinical diagnosis of NAFLD and meet
one of the following criteria :

- a) A historical liver biopsy within 6 months of Screening consistent with NASH
and bridging fibrosis (F3) or within 12 months of Screening consistent with NASH
and compensated cirrhosis (F4) in the opinion of the investigator,

- b) Screening liver stiffness by MRE ≥ 3.64 kPa;

- c) Screening liver stiffness by FibroScan® ≥ 9.9 kPa;

Key Exclusion Criteria:

- Pregnant or lactating females

- Other causes of liver disease including autoimmune, viral, and alcoholic liver disease

- Any history of decompensated liver disease, including ascites, hepatic encephalopathy
or variceal bleeding

- For Cohorts 7 and 8, Child-Pugh-Turcotte (CPT) score > 6

- History of liver transplantation

Note: Other protocol defined Inclusion/Exclusion criteria may apply.